Who is sponsoring NCT05722275?

NCT05722275 is sponsored by Chinese Academy of Sciences.

What drugs are being tested in NCT05722275?

Interventions in NCT05722275: Peritoneal metastasis status ascertainment.

What condition does NCT05722275 study?

NCT05722275 studies Gastric Cancer, Peritoneal Metastases.

Is NCT05722275 still recruiting?

NCT05722275 is currently recruiting now. Last updated 14 February 2023.

Last reviewed 2023-02-14 · How we verify

NCT05722275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Recruiting now Last updated 14 February 2023

What this trial tests

trial testing Peritoneal metastasis status ascertainment in Gastric Cancer in 400 participants. Currently enrolling.

Timeline

1 January 2023

Primary endpoint
31 December 2023

31 December 2028

Quick facts

Lead sponsor	Chinese Academy of Sciences
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	1 January 2023
Primary completion	31 December 2023
Estimated completion	31 December 2028
Sites	13 locations across China, Italy

Drugs / interventions tested

Peritoneal metastasis status ascertainment

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
Peritoneal Metastases — all drugs for Peritoneal Metastases →

Sponsor

Chinese Academy of Sciences — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer or Peritoneal Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Role of Artificial Intelligence in the Management of Gastric Cancer.
Liatsou E, Driva TS, Vergadis C, Sakellariou S, et al · · 2025 · PMID 41462951 · DOI 10.3390/biomedicines13122939

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Chinese Academy of Sciences trials

Trials by the same sponsor.

NCT07170345 — Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion · recruiting
NCT07158372 — Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning · recruiting
NCT06989177 — Probiotic Intervention on Body Weight · NA · recruiting
NCT06989203 — Protein Supplementation Intervention on Body Weight · NA · recruiting
NCT06035250 — AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05722275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Sciences
Last refreshed: 14 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05722275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing